Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:31:28 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:NVRO from 2023-05-03 to 2024-05-02 - 25 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-17 08:30U:NVRONews ReleaseNevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
2024-02-28 16:10U:NVRONews ReleaseNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
2024-02-21 16:06U:NVRONews ReleaseNevro Enters Into Cooperation Agreement With Engaged Capital
2024-02-21 16:05U:NVRONews ReleaseNevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
2024-02-01 16:30U:NVRONews ReleaseNevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
2024-01-29 16:30U:NVRONews ReleaseNevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
2024-01-22 05:01U:NVRONews ReleaseTop 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)
2024-01-18 16:15U:NVRONews ReleaseNevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
2024-01-17 16:15U:NVRONews ReleaseNevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting
2024-01-09 08:30U:NVRONews ReleaseNevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
2024-01-04 16:15U:NVRONews ReleaseNevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-11-30 17:19U:NVRONews ReleaseNevro Announces Acquisition of Vyrsa ¢ „ ¢ Technologies
2023-11-20 07:00U:NVRONews ReleaseNevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain
2023-11-01 16:01U:NVRONews ReleaseNevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
2023-10-04 07:00U:NVRONews ReleaseNevro to Report Third Quarter 2023 Financial Results
2023-09-18 07:00U:NVRONews ReleaseNew Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy
2023-08-23 07:00U:NVRONews ReleaseNevro Announces Participation in Upcoming Investor Conferences
2023-08-16 07:00U:NVRONews ReleaseNew 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
2023-08-01 16:03U:NVRONews ReleaseNevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
2023-07-13 07:00U:NVRONews ReleaseNevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference
2023-07-12 07:00U:NVRONews ReleaseNevro to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-06-27 07:00U:NVRONews ReleaseNevro to Report Second Quarter 2023 Financial Results
2023-06-23 07:00U:NVRONews ReleaseNevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions
2023-06-05 16:05U:NVRONews ReleaseNevro Names New Chief Commercial Officer
2023-05-22 07:00U:NVRONews ReleaseNevro to Present at Jefferies Healthcare Conference